Bradley F. Boeve is a neurologist with subspecialty training in behavioral neurology and sleep medicine. He is interested in the clinical, neuropsychological, electrophysiologic, genetic, biofluid, neuroimaging and neuropathologic aspects of neurodegenerative disorders that manifest as cognitive impairment and/or parkinsonism, including Alzheimer’s disease, Lewy body disease, REM sleep behavior disorder (RBD), frontotemporal lobar degeneration, progressive supranuclear palsy and amyotrophic lateral sclerosis. Dr. Boeve is the coordinating center principal investigator (PI) for the Lewy Body Dementia Association Research Centers of Excellence program, co-PI of the Longitudinal Imaging Biomarkers of Disease Progression in Prodromal DLB U01 protocol at the Mayo Clinic and co-PI of the North American Prodromal Synucleinopathy, Stage 2 (NAPS2) U19 protocol focused on RBD. He plans on integrating alpha-synuclein seed amplification assays with additional clinical, biofluid and neuroimaging data to prepare disease-modifying therapies for Parkinson’s disease and related synucleinopathies.